P6

Background Tamoxifen, a selective estrogen receptor modulator, remains a standard of endocrine therapy for estrogen receptor alpha (ER α ) positive breast cancer (Goldhirsch et al., 2013). Despite well-known advantages of tamoxifen treatment, approximately one third of patients experience a relapse...

Full description

Bibliographic Details

Published in:	European journal of cancer supplements Vol. 13; no. 1; pp. 2 - 3
Main Authors:	Babyshkina, N, Vtorushin, S, Patalyak, S, Dronova, T, Slonimskaya, E, N.Cherdyntseva
Format:	Journal Article
Language:	English
Published:	Elsevier 01-11-2015
Subjects:	Hematology, Oncology and Palliative Medicine
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!